Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Non-Current Debt: 2021

  • Whitehawk Therapeutics' Non-Current Debt was N/A to $5.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $5.8 million, marking a year-over-year change of. This contributed to the annual value of $5.8 million for FY2021, which is N/A change from last year.
  • Per Whitehawk Therapeutics' latest filing, its Non-Current Debt stood at $5.8 million for Q4 2021, which was down 0.00% from $5.8 million recorded in Q3 2021.
  • In the past 5 years, Whitehawk Therapeutics' Non-Current Debt ranged from a high of $5.8 million in Q3 2021 and a low of $5.8 million during Q3 2021.
  • In the last 1 years, Whitehawk Therapeutics' Non-Current Debt had a median value of $5.8 million in 2021 and averaged $5.8 million.